Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2022

Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC)

JP Delord, et al. ASCO 2022 Abstract available on the ASCO website – Download the poster here Poster Presentation

Published 6 June 2022
Categorized as 2022, Myvac, Publication, TG4050

Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022

Transgene presented additional Phase I Data with TG4050 at ASCO 2022

Published 6 June 2022
Categorized as 2022, 2022, Press release, Invir.IO, Myvac, Press release, TG4050

Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022

Transgene to present updated positive preliminary data at ASCO 2022

Published 27 May 2022
Categorized as 2022, 2022, Press release, Invir.IO, Myvac, Press release, TG4050

Transgene’s Combined General Meeting of May 25, 2022

Transgene’s combined general meeting of May 25, 2022

Published 25 May 2022
Categorized as 2022, 2022, Press release, Invir.IO, Press release

Transgene Announces Upcoming Investor Meetings

Transgene annonces upcoming investor meetings

Published 17 May 2022
Categorized as 2022, 2022, Press release, Invir.IO, Press release

All of Transgene’s preclinical and clinical assets progressed in line with expectations in Q1 2022

All of Transgene’s preclinical and clinical assets progressed in line with expectations in Q1 2022

Published 10 May 2022
Categorized as 2022, 2022, Press release, Invir.IO, Press release

Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination

Rodrigo Nalio Ramos, et al. Clinical and Translational Immunology, May 8 2022 – Read the article Publication

Published 8 May 2022
Categorized as -others, 2022, Publication

Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administrationin patients with advanced gastrointestinal carcinomas

V. Moreno, et al. ESMO 2022 – Download the Poster

Published 17 April 2022
Categorized as 2022, Publication, TG6002

Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients

MS Block et al. AACR 2022 Download the publication here

Published 12 April 2022
Categorized as 2022, Myvac, TG4050

Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF

JB Marchand et al. AACR 2022 Abstract available on the AACR website – Download the poster

Published 11 April 2022
Categorized as 2022, BT-001, Publication

Posts pagination

Newer posts Page 1 Page 2 … Page 4 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu